MX369345B - Procesos para la preparacion de analogos de oxitocina. - Google Patents

Procesos para la preparacion de analogos de oxitocina.

Info

Publication number
MX369345B
MX369345B MX2016016050A MX2016016050A MX369345B MX 369345 B MX369345 B MX 369345B MX 2016016050 A MX2016016050 A MX 2016016050A MX 2016016050 A MX2016016050 A MX 2016016050A MX 369345 B MX369345 B MX 369345B
Authority
MX
Mexico
Prior art keywords
preparation
oxytocin
alkyl
processes
oxytocin analogues
Prior art date
Application number
MX2016016050A
Other languages
English (en)
Other versions
MX2016016050A (es
Inventor
Puentener Kurt
Bleicher Konrad
CUENI Anton
SHIINA Junichi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016016050A publication Critical patent/MX2016016050A/es
Publication of MX369345B publication Critical patent/MX369345B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/16Oxytocins; Vasopressins; Related peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a un nuevo proceso para la preparación de análogos de oxitocina de la fórmula (I), en la que R1 es hidrógeno o alquilo-C1-7 y R2 es hidrógeno o alquilo-C1-7; o R1 y R2 junto con el nitrógeno y el átomo de carbono al que están unidos forman un heterociclo de 5 miembros que está opcionalmente sustituido con hidroxi o halógeno; R3 es alquilo-C1-7. Análogos de oxitocina de la fórmula I actúan como agonistas del receptor de oxitocina y tienen el potencial de ser utilizados para el tratamiento de trastornos neurológicos.
MX2016016050A 2014-08-07 2015-08-04 Procesos para la preparacion de analogos de oxitocina. MX369345B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14180161 2014-08-07
PCT/EP2015/067881 WO2016020349A1 (en) 2014-08-07 2015-08-04 Processes for the preparation of oxytocin analogues

Publications (2)

Publication Number Publication Date
MX2016016050A MX2016016050A (es) 2017-02-28
MX369345B true MX369345B (es) 2019-11-06

Family

ID=51298582

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016050A MX369345B (es) 2014-08-07 2015-08-04 Procesos para la preparacion de analogos de oxitocina.

Country Status (19)

Country Link
US (1) US20170174725A1 (es)
EP (1) EP3177635B1 (es)
JP (1) JP6744293B2 (es)
KR (1) KR20170040231A (es)
CN (1) CN106573958A (es)
AU (1) AU2015299118B2 (es)
CA (1) CA2954228A1 (es)
ES (1) ES2700586T3 (es)
HK (1) HK1231495A1 (es)
HR (1) HRP20181916T1 (es)
IL (1) IL248981B (es)
MX (1) MX369345B (es)
MY (1) MY178266A (es)
PL (1) PL3177635T3 (es)
RU (1) RU2696276C2 (es)
SG (1) SG11201700877PA (es)
SI (1) SI3177635T1 (es)
TR (1) TR201815872T4 (es)
WO (1) WO2016020349A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2907454C (en) 2013-03-21 2021-05-04 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
EP2976325B1 (en) 2013-03-21 2017-03-01 Sanofi-Aventis Deutschland GmbH Synthesis of cyclic imide containing peptide products
SI3666258T1 (sl) 2014-09-19 2024-04-30 Ferring Bv Postopek zdravljenja Prader-Willijevega sindroma
EP3852723A4 (en) 2018-09-20 2022-06-29 Levo Therapeutics, Inc. Stable intranasal formulations of carbetocin
TW202034899A (zh) 2018-09-20 2020-10-01 克里斯托弗 S 布萊恩特 卡貝縮宮素藥品及其製備方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2063979C1 (ru) * 1992-02-24 1996-07-20 Всесоюзный научно-исследовательский институт технологии кровезаменителей и гормональных препаратов Пептиды последовательности окситоцина
JP3576554B2 (ja) * 1993-09-21 2004-10-13 協和醗酵工業株式会社 新規ペプチド
FI20021763A0 (fi) * 2002-10-03 2002-10-03 Karyon Oy Ab Ltd Uusia terapeuttisesti aktiivisia aineita ja niiden käyttö
JP4564375B2 (ja) * 2004-08-18 2010-10-20 太陽化学株式会社 テアニンの製造方法
DK2935312T3 (en) * 2012-12-21 2018-10-22 Hoffmann La Roche Peptides as oxytocin agonists

Also Published As

Publication number Publication date
KR20170040231A (ko) 2017-04-12
AU2015299118A1 (en) 2016-12-01
IL248981B (en) 2021-02-28
RU2696276C2 (ru) 2019-08-01
ES2700586T3 (es) 2019-02-18
IL248981A0 (en) 2017-01-31
EP3177635B1 (en) 2018-10-03
JP6744293B2 (ja) 2020-08-19
MX2016016050A (es) 2017-02-28
JP2017527545A (ja) 2017-09-21
CA2954228A1 (en) 2016-02-11
US20170174725A1 (en) 2017-06-22
PL3177635T3 (pl) 2019-02-28
TR201815872T4 (tr) 2018-11-21
EP3177635A1 (en) 2017-06-14
AU2015299118B2 (en) 2020-07-09
HRP20181916T1 (hr) 2019-01-11
SG11201700877PA (en) 2017-03-30
SI3177635T1 (sl) 2019-01-31
CN106573958A (zh) 2017-04-19
RU2017105184A (ru) 2018-09-07
HK1231495A1 (zh) 2017-12-22
MY178266A (en) 2020-10-07
RU2017105184A3 (es) 2019-02-15
WO2016020349A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
NZ730724A (en) Novel methyl-piperidine compounds useful for inhibiting microsomal prostaglandin e2 synthase-1
PH12018500268A1 (en) 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
GEP20186864B (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
MX2016016050A (es) Procesos para la preparacion de analogos de oxitocina.
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
PH12016501941A1 (en) Use of heterocyclic compounds for controlling nematodes
PH12018550165A1 (en) An improved process for the preparation of butorphanol tartrate
MX2017008280A (es) Proceso para elaborar cenicriviroc y analogos relacionados.
PH12016501613B1 (en) Pyrazines modulators of gpr6
PH12019500198A1 (en) Compounds and compositions and uses thereof
MY188420A (en) Crystalline forms of (s)-afoxolaner
PH12017501560A1 (en) Tetrahydropyranyl benzamide derivatives
PH12017500492A1 (en) Crystalline bace inhibitors
MX2016015959A (es) Derivados de carbamato los cuales son tanto inhibidores de la enzima fosfodiesterasa 4 (pde4) como antagonistas del receptor muscarinico m3.
MX2023001906A (es) Diarilureas como moduladores alostericos de cannabinoide cb1.
PH12016501808B1 (en) Chemical compounds
IN2014MU00069A (es)

Legal Events

Date Code Title Description
FG Grant or registration